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Abstract
In rats, oligofructose has been shown to stimulate satiety hormone secretion, reduce energy intake and promote weight loss. The present
study aimed to examine the effect of oligofructose supplementation on appetite profiles, satiety hormone concentrations and energy
intake in human subjects. A total of thirty-one healthy subjects (ten men and twenty-one women) aged 28 (SEM 3) years with a BMI of
24·8 (SEM 0·3) kg/m2 were included in a randomised double-blind, cross-over study. The subjects received 10 g oligofructose, 16 g oligofruc-
tose or 16 g placebo (maltodextrin) daily for 13 d, with a 2-week washout period between treatments. Appetite profile, active glucagon-like
peptide 1 (GLP-1) and peptide YY3-36 (PYY) concentrations and energy intake were assessed on days 0 and 13 of the treatment period.
Time £ treatment interaction revealed a trend of reduction in energy intake over days 0–13 by oligofructose (P¼0·068). Energy intake was
significantly reduced (11 %) over time on day 13 compared with day 0 with 16 g/d oligofructose (2801 (SEM 301) v. 3217 (SEM 320) kJ,
P,0·05). Moreover, energy intake was significantly lower with 16 g/d oligofructose compared with 10 g/d oligofructose on day 13 (2801
(SEM 301) v. 3177 (SEM 276) kJ, P,0·05). Area under the curve (AUC) for GLP-1 on day 13 was significantly higher with 16 g/d oligofructose
compared with 10 g/d oligofructose (45 (SEM 4) v. 41 (SEM 3) pmol/l £ h, P,0·05). In the morning until lunch, AUC0–230 min for PYY on day
13 was significantly higher with 16 g/d oligofructose compared with 10 g/d oligofructose and placebo (409 (SEM 35) v. 222 (SEM 19) and 211
(SEM 20) pg/ml £ h, P,0·01). In conclusion, 16 g/d and not 10 g/d oligofructose may be an effective dose to reduce energy intake, possibly
supported by higher GLP-1 and PYY concentrations.
Key words: Energy intake: Visual analogue scales: Inulin-type fructans
The prevalence of obesity has increased worldwide to epidemic
proportions. Weight gain occurs when energy intake exceeds
energy expenditure for a prolonged period of time. Therefore,
novel foods that promote satiety and thereby reduce energy
intake may be promising tools in weight management. A poten-
tial candidate ingredient for such foods is oligofructose, a
fructan obtained as a partial enzymatic hydrolysate from chicory
root inulin. It is fermented in the colon, and it is especially
known for its prebiotic effects and associated physiological
effects(1–3).
The hypothesis that oligofructose might have beneficial
effects on energy intake is based upon rat studies(4,5). In rats,
energy intake was decreased over time in the animals fed with
oligofructose compared with the animals fed with a control
diet. This resulted in a decrease in epididymal fat mass and
visceral adipose tissue at the end of the treatment(6,7).
In addition, glucagon-like peptide 1 (GLP-1) amide and pro-
glucagon mRNA concentrations were found to be higher in
the oligofructose-fed rats(6,7). GLP-1 is released from enteroen-
docrine L-cells in response to nutrient ingestion. Fermentation
of oligofructose into SCFA in the gut has been shown to pro-
mote enteroendocrine L-cell differentiation in the proximal
colon by up-regulation of the differentiation factors (neuro-
genin 3 and NeuroD), thereby contributing to a higher
endogenous GLP-1 production(8). GLP-1 was found to be
essential in the control of food intake by oligofructose, since
the beneficial effects of oligofructose were totally prevented
in the presence of a GLP-1 receptor antagonist(9). In addition,
GLP-1 receptor knockout mice (GLP-1R2/2) were completely
insensitive to the actions of oligofructose(9).
Although animal studies suggest that oligofructose may be
a promising tool in the nutritional approach in controlling
obesity, only a few studies have investigated the effect of
oligofructose in human subjects. For instance, plasma GLP-1
concentrations significantly increased after oligofructose
feeding of 20 g/d for 7 d in patients with gastro-oesophageal
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reflux disease(10). It also has been demonstrated that inulin-
type fructans, added in food as fat replacement, were able
to lower energy intake(11). In a pilot study by Cani et al.(12),
a 2-week treatment with 16 g/d oligofructose has been
shown to promote satiety following breakfast and dinner,
and to reduce hunger and prospective food consumption
following dinner. Total energy intake per d was 5 % lower
during the oligofructose treatment than during the control
treatment(12). These investigators(13) also showed that a differ-
ent type of inulin consumption of 16 g/d led to increased
plasma levels of GLP-1 and peptide YY3-36 (PYY). Recently,
a 12-week treatment with 21 g/d oligofructose has been
shown to increase the area under the curve (AUC) for the
anorexigenic hormone PYY and to decrease the AUC for
the orexigenic hormone ghrelin(14). Self-reported energy
intake was significantly lower in the oligofructose group,
and there was a reduction in body weight of about 1 kg
over 12 weeks(14).
However, information on the minimal dosage of oligofruc-
tose necessary for establishing beneficial effects is still lacking.
Therefore, we performed a placebo-controlled cross-over
study to examine the effect of 10 and 16 g/d oligofructose
for 13 d on the appetite profile, GLP-1 and PYY concentrations
and energy intake in normal-weight and overweight men
and women.
Subjects and methods
Subjects
A total of thirty-one healthy subjects (ten men and twenty-one
women) aged 20–60 years with a BMI of 23–28 kg/m2 were
recruited by advertisements in local newspapers and on
notice boards at the university. The subjects underwent a
screening, and all were in good health, non-smokers, not
using medication (except oral contraception) and moderate
alcohol users. None of the subjects had a food allergy,
gained or lost more than 5 kg in 3 months before the study,
or were cognitive dietary restrained (F1 . 9) as assessed
by a validated Dutch translation of the Three-Factor Eating
Questionnaire(15). The present study was conducted according
to the guidelines laid down in the Declaration of Helsinki, and
all procedures involving human subjects were approved
by the Central Committee on Human Research and by the
Medical Ethics Committee of the University of Maastricht
(Maastricht, The Netherlands). Written informed consent was
obtained from all subjects.
Study design
The study had a randomised, placebo-controlled cross-over
design. It consisted of three 13 d supplementation periods,
wherein oligofructose (Fructalosew L92, 10 or 16 g; Sensus,
Roosendaal, The Netherlands) or placebo (maltodextrin,
16 g) supplements were consumed daily, separated by a
2-week washout period. Maltodextrin was selected as a
placebo following previous studies on the effect of oligofruc-
tose(12,14). Furthermore, maltodextrin has a similar taste and
appearance as oligofructose. The supplements were provided
in one-shot fruit drinks of 100 ml. Daily supplements were
divided into two equal portions of either 5 or 8 g, each to
be consumed at home during breakfast and lunch. To deter-
mine compliance, the subjects kept the empty bottles and
handed them in on later visits to the university. Potential
adverse effects including flatulence, bloated feeling, abdomi-
nal rumbling and abdominal pain were monitored daily
using a diary. The subjects were asked not to gain or lose
weight consciously and to avoid pre- and probiotic foods as
indicated on a provided list of food products. The subjects
reported to the university six times at 08.00 hours after an
overnight fast on days 0 and 13 of each intervention interval.
They were asked to abstain from strenuous physical activity
and alcohol, and not to eat or drink from 22.00 hours the
night before each test day. Energy intake and appetite profile
ratings were determined on days 0 and 13. GLP-1 and PYY
concentrations were determined on day 13.
Study protocol
On each test day, the subject’s body weight was measured
with minimal clothing in the fasting state. The subjects
received a standardised breakfast at 08.30 hours consisting
of 20 % of the subject’s individual daily energy requirements.
Subject-specific daily energy requirements were derived
from BMR, which was calculated from the equation of
Harris–Benedict(16). BMR was multiplied by an activity index
of 1·5, as indicated for a sedentary day(17). Breakfast consisted
of brown bread with cheese and marmalade, and fruit yogurt
(21, 62 and 17 En % from protein, carbohydrate and fat,
respectively). At 12.30 hours, the subjects received a standar-
dised lunch, which provided 40 % of the subject’s individual
daily energy requirements. The lunch consisted of brown
bread with egg and tuna sandwich salad, tomato soup and
grape juice (18, 55 and 27 En % from protein, carbohydrate
and fat, respectively). Food and energy intake were assessed
on days 0 and 13 via an ad libitum dinner at 17.00 hours,
which consisted of a homogeneous hot pasta meal. The
dinner was weighed before and after eating. The subjects
were instructed to eat till they were comfortably full.
The lasagna (1350 g) provided 5 kJ/g (31, 45 and 24 En %
from protein, carbohydrate and fat, respectively). Appetite
profile ratings were measured sixteen times with regular inter-
vals between 08.30 and 20.00 hours on days 0 and 13. On day
13, nine blood samples were collected at 08.20, 09.00, 09.30,
10.30, 12.20, 13.00, 13.30, 14.30 and 15.30 hours, respectively,
in order to obtain GLP-1 and PYY concentrations over the day.
Appetite profile
Appetite profile ratings were evaluated using anchored
100 mm visual analogue scales (VAS)(18,19). Hunger, fullness,
satiety, thirst, desire to eat and prospective food consumption
were measured. The scale was anchored from ‘not at all’ on
the left to ‘extremely’ on the right. The participants were
instructed to rate their feelings by marking the scale with a
vertical line at a point that was most appropriate at that
S. P. M. Verhoef et al.1758
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time. The distance from the left end of the scale to this vertical
line on the scale was measured in mm; changes from baseline
were calculated by subtracting the baseline score from the
score at a certain time point. On each test day, these question-
naires were completed at 08.30, 09.00, 09.30, 10.30, 11.30,
12.30, 13.00, 13.30, 14.30, 15.30, 16.30, 17.00, 17.30, 18.00,
19.00 and 20.00 hours.
Blood sampling
On days 0 and 13, a catheter was placed into the antecubital
vein for blood sampling. Blood samples were collected into
tubes containing EDTA, 10ml dipeptidyl peptidase IV per ml
blood and 50ml aprotonin per ml blood for measurements
of PYY concentrations. For GLP-1 measurements, blood was
collected into EDTA tubes containing 10ml dipeptidyl pepti-
dase IV per ml blood. Plasma was obtained by centrifugation
(48C, 1000 g, 10 min) and stored at 2808C until analysed.
PYY3-36 concentrations were measured with a specific and
sensitive RIA (Linco Research, Inc., St Charles, MO, USA).
Plasma-active GLP-1 concentrations were measured by
enzyme-linked immunoradiometric assay (EGLP-35K; Linco
Research, Inc.).
Statistical analysis
Data are presented as mean changes from baseline with their
standard errors, unless otherwise indicated. AUC of changes
from baseline over time was calculated by using the trapezoid
method. A Student’s t test (two-tailed distribution) was carried
out to determine the possible differences between the con-
ditions. ANOVA repeated measures was carried out with a
repeated covariance structure to determine possible differ-
ences in appetite ratings and energy intake between
conditions and time £ treatment interactions. Significance
was defined as P,0·05. All the statistical analyses were
executed with SPSS version 16.0 for Macintosh OS X (SPSS,
Inc., Chicago, IL, USA).
Results
Subject characteristics
Of the thirty-one subjects, two dropped out because of
personal reasons, and twenty-nine subjects (nine men and
twenty women) completed the study. The baseline character-
istics of these subjects are presented in Table 1. As expected,
body weight and height were significantly different between
men and women. Body weight did not change over time,
and there were no significant differences in body weight
between the conditions. Moreover, no sex differences were
present with respect to changes in measured variables, so
the whole group was analysed together.
Appetite profile
On day 0, the AUC for appetite profile ratings was
not significantly different between the three conditions.
No time £ treatment differences were present with respect to
the appetite profile ratings.
Peptide YY3-36 and glucagon-like peptide 1
Fasting PYY concentrations, but not fasting GLP-1 concen-
trations, were significantly lower on day 13 compared with
those on day 0 in all conditions (49·9 (SEM 4·4) v. 71·2
(SEM 3·9) pg/ml for placebo; 46·9 (SEM 4·6) v. 71·9 (SEM
3·6) pg/ml for 10 g/d oligofructose and 53·8 (SEM 4·7) v. 74·1
(SEM 3·9) pg/ml for 16 g/d oligofructose; P,0·01).
After the meals, PYY concentrations significantly increased
in all conditions (Fig. 1(a) and (b), P,0·05). In the morning
until lunch, AUC0–230 min for PYY was significantly higher
with 16 g/d oligofructose than with 10 g/d oligofructose and
placebo (409 (SEM 35) v. 222 (SEM 19) and 211 (SEM 20)
pg/ml £ h, P,0·01). This gradually diminished over the day,
resulting in a trend towards a larger total AUC for PYY with
16 g/d oligofructose than with 10 g/d oligofructose or placebo
(P¼0·065).
After the meals, GLP-1 concentrations also increased signifi-
cantly in all conditions (Fig. 1(c) and (d), P,0·05). AUC
for GLP-1 was significantly higher with 16 g/d oligofructose
compared with 10 g/d oligofructose (P,0·05). In addition,
AUC for GLP-1 with 10 g/d oligofructose was significantly
lower compared with placebo (P,0·05).
Compliance and side effects
Compliance was high, as shown by the empty packages
returned at the end of each treatment. Incidentally, some
subjects returned a full package, indicating a missed dose.
The subjects also reported this in their diary, showing that
missing doses remained below 5 %. Only a small proportion
of these missing doses was on the day before the measure-
ments, and no doses were missed on the day of the
measurements.
Adverse effects, such as flatulence, abdominal rumbling,
bloated feeling and cramps, were significantly higher for 10
and 16 g/d oligofructose compared with placebo on several
days during the treatment, respectively (P,0·05, data not
shown). However, none of the subjects complained about
side effects, and there were no significant time £ treatment
interactions. Also, side effects did not influence compliance,
Table 1. Subject characteristics
(Mean values with their standard errors)
Total (n 29) Men (n 9) Women (n 20)
Mean SEM Mean SEM Mean SEM
Age (years) 28 3 32 6 26 3
Height (m) 1·73 0·02 1·80 0·03 1·70* 0·02
Body weight (kg) 74·7 2·0 83·1 3·8 70·9* 1·8
BMI (kg/m2) 24·8 0·3 25·5 0·6 24·5 0·4
Dietary restraint† 6·0 0·6 4·8 1·0 6·2 0·7
* Mean values were significantly different from those of men (P,0·01, by ANOVA).
† Dietary restraint, factor 1 of the Three-Factor Eating Questionnaire(15).
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since compliance was similar in the placebo treatment as with
10 and 16 g/d oligofructose.
Energy intake
On day 0, energy intake during the ad libitum dinner was
similar for all the conditions (2788 (SEM 251), 3127 (SEM 267)
and 3217 (SEM 321) kJ for placebo, 10 and 16 g/d oligofructose,
respectively). Subsequently, energy intake was significantly
lower on day 13 after the 16 g/d oligofructose treatment
(11 %, P,0·05) compared with 10 g/d oligofructose (2801
(SEM 301) v. 3177 (SEM 276) kJ, P,0·05; Fig. 2), but not com-
pared with placebo (2979 (SEM 276) kJ).
Discussion
In the present study, the effect of oligofructose supplemen-
tation on appetite profiles, satiety hormone concentrations
and energy intake in human subjects was examined. Energy
intake decreased over time with 16 g/d oligofructose, whereas
consumption of 10 g/d oligofructose did not change energy
intake. There were no significant associations of the oligofruc-
tose-induced reduction in energy intake with appetite profile
ratings.
Reduced energy intake on day 13, with 16 g/d oligofructose
was underscored by higher AUC0–230 min of PYY hormone
concentrations with 16 g/d oligofructose compared with
10 g/d oligofructose and placebo, and higher AUCtotal
of GLP-1 hormone concentrations with 16 g/d oligofructose
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Fig. 1. Mean values for (a) plasma peptide YY3-36 (PYY; time £ treatment
interaction P¼0·065) and (b) active glucagon-like peptide 1 (GLP-1; time £
treatment interaction P¼0·041) concentrations during day 13 as absolute
concentrations (pg/ml, pmol/l) with breakfast consumed at 10 min and lunch
at 250 min, (c) area under the curve (AUC) for PYY3-36 and (d) AUC for
active GLP-1 (pg/mml £ h, pmol/l £ h). 16 g/d oligofructose ( , ), 10 g/d
oligofructose ( , ) and placebo ( , ). Data were analysed by
ANOVA with repeated measures. * Mean values were significantly different
between 16 g/d oligofructose and 10 g/d oligofructose (P,0·05). † Mean
values were significantly different between 16 g/d oligofructose and placebo
(P,0·05). ‡ Mean values were significantly different between 10 g/d oligo-
fructose and placebo (P,0·05). § Mean values were significantly different
between 10 g/d oligofructose and 16 g/d oligofructose and placebo (P,0·05).
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Fig. 2. Changes in energy intake (kJ) between days 0 and 13 after placebo
( ), 10 g/d oligofructose ( ) and 16 g/d oligofructose ( ) treatment.
Data were analysed by ANOVA with repeated measures. * Mean values
were significantly different from baseline (P,0·05). † Mean values were
significantly different between the conditions for time £ treatment interaction
(P¼0·068).
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compared with 10 g/d oligofructose, although not significantly
different from placebo. Based on rat studies(6,7,9), it is
suggested that oligofructose intake results in increased
GLP-1 and PYY concentrations mediated via the SCFA,
which are produced by the fermentation of oligofructose.
Previous studies in human subjects showed an increased
AUC for PYY with 21 g/d oligofructose, whereas GLP-1 did
not change(14). Moreover, fasting PYY concentrations on day
13 compared with day 0 were decreased in all conditions,
suggesting an effect not specifically due to oligofructose
consumption. However, the subjects may have experienced
a different feedback of SCFA from the colon due to the
consumption of a different macronutrient and particularly
fibre composition in general, resulting in an overall reduction
of PYY.
The results on appetite profile ratings suggest that oligofruc-
tose does not suppress appetite. This is not consistent with
previous findings(12). On the other hand, Archer et al.(11)
could not find an effect for inulin on appetite at a lower
dosage, but they did find a decrease in energy intake.
However, differences in study design, such as standardised
meals v. ad libitum and free-choice meals, and differences
in population size and type of inulin used complicate com-
parisons between studies. In addition, measuring subjective
appetite ratings with VAS can result in high variability(18,19).
Probably, oligofructose does not affect appetite feelings
sufficiently to be detected with the use of VAS.
Observations on side effects as reported in the literature are
not consistent. Several measurement methods are used, such
as diaries, questionnaires with four-point scales(20) or VAS
questionnaires(14). In addition, some studies report about side
effects without explaining the measurement procedures(12)
or do not report about side effects at all(11). This makes it
difficult to compare results between studies. We combined
the VAS questionnaires with diaries to analyse occurrence
of side effects over time. Consumption of 10 and 16 g
oligofructose daily for 2 weeks did result in minor gastrointesti-
nal side effects. However, no subjects complained; compliance
was not affected by side effects, and we did not observe a
relation of side effects with energy intake.
The observed reduction in energy intake induced by 16 g/d
oligofructose over a time interval of 13 d is in agreement with
earlier findings(12,14). However, differences between 16 g/d
oligofructose and placebo were not significant. Since the
placebo is a polysaccharide, there might be an effect of
16 g/d maltodextrin itself on energy intake, through which
the differences between placebo and 16 g/d oligofructose
become too small in order to reach significance. Maltodextrin,
in higher concentrations (62·9 g), has been shown to lower
energy intake(21).
Energy intake did not change with 10 g/d oligofructose.
This suggests that only 16 g/d oligofructose is a minimal
dosage to induce an effect of oligofructose on energy intake.
The present results suggest that oligofructose-induced
reduction in energy intake might be exerted via increased
GLP-1 and PYY concentrations.
A limitation of the present study is the nature of the treat-
ment. With such a minimal dosage, i.e. 16 g/d compared
with 21 g/d in other studies, the study needs more sensitivity.
A larger number of subjects and a longer period of time
may have shown more robust results. However, we found
for consumption of 16 g/d oligofructose a trend for a time £
treatment effect over 13 d, as well as lower energy intakes
on the final day of treatment. The latter was supported
by higher AUC concentrations of GLP-1 and for PYY in the
morning. Another limitation of the present study is that we
did not measure SCFA. Although measuring SCFA in vivo in
human subjects is challenging, combining SCFA measurements
in both faeces and blood could contribute to explaining
the mechanism behind the effect of oligofructose on
energy intake.
In conclusion, 16 g/d and not 10 g/d oligofructose may be
an effective dose to reduce energy intake in normal-weight
and overweight men and women, underscored by elevated
GLP-1 and PYY concentrations.
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